Industry Updates

Orexigen wows analysts with IIb obesity data – FierceBiotech30 Sep

A brilliant move from local biotech Orexigen – combine an existing obesity drug candidate with an antidepressant for a potential blockbuster coctail. Patients in this IIb (mid-late) stage trial lost a whopping 9.9% of body weight during the 24 week period, averaging 22 pounds. And I’ll bet they had fun doing it too!

http://www.fiercebiotech.com/story/orexigen-wows-analysts-iib-obesity-data/2009-09-30?utm_medium=nl&utm_source=internal

Leave a Reply

Company News

  • - 2010/03/01

    We're currently working with the Life Sciences IT Global Institute to define Good Informatics Practices for Data Management in Life Sciences and Healthcare, and working on solutions in data mining for scientific applications. Contact us to find out more!

  • - 2010/01/11

    Our current project is with the Software Engineering team of a large local biotech firm, where we are applying our expertise in automation to the question of whether an upgrade to the latest version of third party vendor tool is appropriate in their FDA regulated environment.

Contact Us

Email contact@dotgentech.com

DOTGEN TECHNOLOGIES INC.
PO BOX 4095
San Diego, CA 92164-4095